Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients with Gastric, GEJ and Oesophageal Adenocarcinoma By Ogkologos - February 24, 2026 245 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 5 years of follow-up of CheckMate 649 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR ctDNA-Guided Treatment Influence on Survival in Advanced NSCLC November 21, 2022 Beating cancer by improving the public’s health: the road ahead in... December 4, 2020 This Breast Cancer Patient Is Using Boudoir Photography to Reclaim Her... November 5, 2019 Understanding the Risk of Second Cancers After CAR T-Cell Therapy August 13, 2024 Load more HOT NEWS Resource Round-Up: Let’s Win Pancreatic Cancer Pattern of DNA Damage Links Colorectal Cancer and Diet High in... FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma EMA Recommends Granting a Marketing Authorisation for Zolbetuximab
